Euro Ewing 2012

Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours

Agents: Different chemotherapy regimens
Phase  III
Status  Open, recruiting
Sponsor University of Birmingham

 

Further information: http://www.euroewing.eu/clinical-trials/ee2012-trial/patients-ee2012

 

WHO is the trial for?

 
  • Patients with diagnosed Ewing’s sarcoma, primitive neuroectodermal tumour, soft tissue Ewing’s tumour
  • Overall health status of the patient has to be good
  • Age between 2 and 50 years

WHAT is the key question that this trial is attempting to answer?

The aim of the Euro Ewing 2012 trial is to compare different chemotherapy regimens to determine which is more effective and/or has fewer side effects.

WHY patients might want to participate?

This trial will further support the research in Ewing’s sarcoma and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN will the trial be open?

The study is open for participation (recruiting)

WHERE is the trial available?

The trial is available in several study centers in the UK, France and Spain. For a complete list of trial locations, please see here. The trial is expected to be to open to patients in Denmark, The Netherlands, Italy and Ireland later on.

Study contact:
If you have any questions about this trial, please contact the Cancer Research UK Clinical Trials Unit at the University of Birmingham This email address is being protected from spambots. You need JavaScript enabled to view it.

 

STUDY DESIGN: What does the study look like?

The trial is comparing two treatments, known as treatment arms A and B.


Treatment arm A is the chemotherapy that is the standard treatment used in Europe whereas treatment arm B is the chemotherapy that is used in the USA. The trial is being run as we do not know which treatment is best.


A second reason for running the trial is to test if a drug called zoledronic acid can improve treatment for Ewing sarcoma. Zoledronic acid has been widely used for the treatment of other bone diseases and cancers that start in or spread to the bone and thus might offer benefits for patients with Ewing sarcoma without worsening the side effects of the chemotherapy.
More details about the trial scheme can be found here.

HOW do I get more information?

Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients. If there are no such organisation in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

SHARE your experience

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

 No results are available at this time. Future results will be linked here.

 

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken

Pin It